
In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.
• ADHD • Allergy • Asthma • Atopic Dermatitis • Autism • Bacterial Conjunctivitis • Developmental/Genetic Disorders • Epilepsy • Failure to Thrive • Food Allergies • GI Disorders • Lice Treatments • Obesity • Respiratory Tract Diseases • Sexually Transmitted Infections • Skin Diseases • Vaccines • Vitamin D Insufficiency
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•






